In sum, our results suggest that the early infiltration of CD8+ TRLs naturally limits infarct expansion in the ischemic brain and that adoptive transfer of CD8+ TRLs offers a potentially novel immunotherapy for stroke. The gene discussed is CD8A; the disease is Stroke.